US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Pulse Biosciences, Inc.
< Previous
1
2
3
4
5
Next >
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
September 15, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
August 06, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
July 30, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
July 29, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
July 21, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 15, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
June 10, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
May 27, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
May 12, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
May 08, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
May 04, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
April 25, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Strengthens Executive Leadership Team
April 09, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
April 07, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
March 17, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
March 12, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
March 09, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
March 05, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
March 04, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
February 20, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
February 19, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
February 05, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
February 04, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
February 03, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
January 09, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
January 06, 2026
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 29, 2025
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
< Previous
1
2
3
4
5
Next >
